Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
EDQM
0
USP
0
JP
0
Others
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
API
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. Aflutinib
2. Ast2818
3. Furmonertinib
4. Furmonertinib Mesylate
5. Ivesa
6. N-(2-(2-(dimethylamino)ethyl-methylamino)-5-((4-(1-methylindol-3-yl)pyrimidin-2-yl)amino)-6-(2,2,2-trifluoroethoxy)pyridin-3-yl)prop-2-enamide
1. 1869057-83-9
2. Furmonertinib
3. Ast2818
4. Ast-2818
5. A49a7a5yn4
6. Ivesa
7. N-[2-[2-(dimethylamino)ethyl-methylamino]-5-[[4-(1-methylindol-3-yl)pyrimidin-2-yl]amino]-6-(2,2,2-trifluoroethoxy)pyridin-3-yl]prop-2-enamide
8. N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((4-(1-methyl-1h-indol-3-yl)pyrimidin-2-yl)amino)-6-(2,2,2-trifluoroethoxy)pyridin-3-yl)acrylamide
9. 2-propenamide, N-(2-((2-(dimethylamino)ethyl)methylamino)-5-((4-(1-methyl-1h-indol-3-yl)-2-pyrimidinyl)amino)-6-(2,2,2-trifluoroethoxy)-3-pyridinyl)-
10. Aflutinib
11. N-(2-(2-(dimethylamino)ethyl-methylamino)-5-((4-(1-methylindol-3-yl)pyrimidin-2-yl)amino)-6-(2,2,2-trifluoroethoxy)pyridin-3-yl)prop-2-enamide
12. Alflutinib (pseudo Inn)
13. Unii-a49a7a5yn4
14. Furmonertinib [who-dd]
15. Chembl4297258
16. Schembl17490447
17. Gtpl10477
18. Bcp30339
19. Example 3 [us10072002b2]
20. Ex-a2868-1
21. Ac-36862
22. Hy-112870
23. Alflutinib;ast-2818;ast 2818;ask120067;ask 120067;ask-120067
Molecular Weight | 568.6 g/mol |
---|---|
Molecular Formula | C28H31F3N8O2 |
XLogP3 | 4.4 |
Hydrogen Bond Donor Count | 2 |
Hydrogen Bond Acceptor Count | 11 |
Rotatable Bond Count | 11 |
Exact Mass | g/mol |
Monoisotopic Mass | g/mol |
Topological Polar Surface Area | 100 |
Heavy Atom Count | 41 |
Formal Charge | 0 |
Complexity | 865 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
Protein Kinase Inhibitors
Agents that inhibit PROTEIN KINASES. (See all compounds classified as Protein Kinase Inhibitors.)
ABOUT THIS PAGE
83
PharmaCompass offers a list of Furmonertinib API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Furmonertinib manufacturer or Furmonertinib supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Furmonertinib manufacturer or Furmonertinib supplier.
PharmaCompass also assists you with knowing the Furmonertinib API Price utilized in the formulation of products. Furmonertinib API Price is not always fixed or binding as the Furmonertinib Price is obtained through a variety of data sources. The Furmonertinib Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Alflutinib manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Alflutinib, including repackagers and relabelers. The FDA regulates Alflutinib manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Alflutinib API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Alflutinib supplier is an individual or a company that provides Alflutinib active pharmaceutical ingredient (API) or Alflutinib finished formulations upon request. The Alflutinib suppliers may include Alflutinib API manufacturers, exporters, distributors and traders.
Alflutinib Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Alflutinib GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Alflutinib GMP manufacturer or Alflutinib GMP API supplier for your needs.
A Alflutinib CoA (Certificate of Analysis) is a formal document that attests to Alflutinib's compliance with Alflutinib specifications and serves as a tool for batch-level quality control.
Alflutinib CoA mostly includes findings from lab analyses of a specific batch. For each Alflutinib CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Alflutinib may be tested according to a variety of international standards, such as European Pharmacopoeia (Alflutinib EP), Alflutinib JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Alflutinib USP).